This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Endocrine disease				
Hypogonadism; muscular atrophy	Androgen receptor	<p>A study in rats identified selective androgen receptor modulator (SARM) derivatives that could be useful for treating hypogonadism-associated conditions such as muscular atrophy. In castrated rats, once-daily treatment with one of the derivatives increased muscle growth with an ED₅₀ value of 0.9 µg/kg. The derivative also showed a 16-fold increase in selectivity for muscle over prostate tissue. Next steps could include using the scaffold as a template for identifying additional SARMS.</p> <p>SciBX 2(16); doi:10.1038/scibx.2009.662 Published online April 23, 2009</p>	Patent and licensing status unavailable	<p>Nirschl, A.A. <i>et al. J. Med. Chem.</i>; published online April 7, 2009; doi:10.1021/jm801583j</p> <p>Contact: Lawrence G. Hamann, Novartis Institutes for Biomedical Research, Emeryville, Calif. e-mail: lawrence.hamann@novartis.com</p> <p>Contact: James C. Sutton, same affiliation as above e-mail: james.sutton@novartis.com</p> <p>Contact: Gary J. Grover, Product Safety Laboratories, Dayton, N.J. e-mail: garygrover@productsafetylabs.com</p> <p>Contact: Stanley R. Krystek Jr., Bristol-Myers Squibb Co., Princeton, N.J. e-mail: stanley.krystek@bms.com</p>